# The Study to Describe Symptom Control and Impact on Daily Life in Gastroesophageal Reflux Disease (GERD) Patients

> **NCT01200550** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1233 (actual)

## Conditions studied

- Gastroesophageal Reflux Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01200550
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2011-09
- **Final completion:** 2011-11
- **Target enrollment:** 1233 (ACTUAL)
- **Last updated:** 2012-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01200550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01200550, "The Study to Describe Symptom Control and Impact on Daily Life in Gastroesophageal Reflux Disease (GERD) Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01200550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*